Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis.
Frequency and relevance of IgM intrathecal synthesis in multiple sclerosis.
Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters.
Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis.
[Assessment of the high cost drug program on an example of the interferon treatment of multiple sclerosis.]
Multiple sclerosis: Daclizumab HYP shows efficacy in patients with relapsing-remitting MS.
Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
Recurrent paraparesis and death of a patient with 'whippet' abuse.
Assessment of a program to encourage the multidisciplinary management of urinary disorders in multiple sclerosis.
Tumefactive demyelinating disease with isolated spinal cord involvement.
Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica.
Neuronal activity biases axon selection for myelination in vivo.
Serum 25(OH) Vitamin D levels is not associated with disability in multiple sclerosis patients: A case-control study.
Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis.
Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.
Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis.
Genetic variation associated with the occurrence and progression of neurological disorders.
Pío del Río Hortega and the discovery of the oligodendrocytes.
Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis.
Meta-Analysis of Multiple Sclerosis Microarray Data Reveals Dysregulation in RNA Splicing Regulatory Genes.
The Nogo/ Nogo-66 receptor (NgR) signal is involved in neuroinflammation through the regulation of microglia inflammatory mediator expression.
"Microglial nodules" and "newly forming lesions" may be a Janus face of early MS lesions; implications from virus-induced demyelination, the Inside-Out model.
Multiple Roles for Nogo Receptor 1 in Visual System Plasticity.
Pages
« first
‹ previous
…
574
575
576
577
578
579
580
581
582
…
next ›
last »